NCT04374240 - A Clinical Trial of AdNRGM Plus CB1954 in Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2013

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions

Prostate Cancer

Interventions

GENETIC

AdNRGM

"AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 \[5-(aziridin-1-yl)-2,4-dinitrobenzamide\]"

Trial Locations (1)

B15 2GW

Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham